{"count": 2, "results": [{"_id": "7180669", "pmid": 7180669, "title": "Comparison of propranolol and atenolol in the control of hyperparathyroidism in uremia.", "journal": "Adv Exp Med Biol", "authors": ["Makdassi R", "Andrejak M", "Morinière P", "Sebert JL", "Decourt S", "Guéris J", "Coevoet B", "Fournier A"], "date": "1982-01-01T00:00:00Z", "doi": "10.1007/978-1-4684-4259-5_68", "meta_date_publication": "1982", "meta_volume": "151", "meta_issue": "", "meta_pages": "667-76", "score": 50083.418, "text_hl": "Comparison of @CHEMICAL_Propranolol @CHEMICAL_MESH:D011433 @@@propranolol@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ in the control of @DISEASE_Hyperparathyroidism @DISEASE_MESH:D006961 @@@hyperparathyroidism@@@ in @<m>DISEASE_Uremia</m> @DISEASE_MESH:D014511 @@@uremia@@@.", "citations": {"NLM": "Makdassi R, Andrejak M, Morinière P, Sebert JL, Decourt S, Guéris J, Coevoet B, Fournier A. Comparison of propranolol and atenolol in the control of hyperparathyroidism in uremia. Adv Exp Med Biol. 1982;151():667-76. PMID: 7180669", "BibTeX": "@article{7180669, title={Comparison of propranolol and atenolol in the control of hyperparathyroidism in uremia.}, author={Makdassi R and Andrejak M and Morinière P and Sebert JL and Decourt S and Guéris J and Coevoet B and Fournier A}, journal={Adv Exp Med Biol}, volume={151}, pages={667-76}}"}}, {"_id": "12071084", "pmid": 12071084, "title": "[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].", "journal": "Praxis (Bern 1994)", "authors": ["Faller J", "Hess B"], "date": "2002-05-08T00:00:00Z", "doi": "10.1024/0369-8394.91.19.836", "meta_date_publication": "2002 May 8", "meta_volume": "91", "meta_issue": "19", "meta_pages": "836-44", "score": 50050.477, "text_hl": "Nevertheless, due to the fact that @SPECIES_9606 @@@patients@@@ reached @<m>DISEASE_Uremia</m> @DISEASE_MESH:D014511 @@@uremia@@@ and had to be dialyzed, 20 years of @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@-based regimen with costs of 316 millions of Swiss francs turned out to be much more expensive than the @CHEMICAL_Lisinopril @CHEMICAL_MESH:D017706 @@@lisinopril@@@- or the @CHEMICAL_Verapamil @CHEMICAL_MESH:D014700 @@@verapamil@@@-based regimen with 121 and 38 millions of Swiss francs, respectively. ", "citations": {"NLM": "Faller J, Hess B. [Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care]. Praxis (Bern 1994). 2002 May 8;91(19):836-44. PMID: 12071084", "BibTeX": "@article{12071084, title={[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].}, author={Faller J and Hess B}, journal={Praxis (Bern 1994)}, volume={91}, number={19}, pages={836-44}}"}}]}